Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease
-
- Stefan Kiechl
- From the Department of Neurology (S.K., G.W., W.P., J.W.), Innsbruck University Clinic, Innsbruck, Austria; Division of Rheumatology (G.S., K.R., J.S.), Department of Internal Medicine III, University of Vienna, Vienna, Austria; and Departments of Internal Medicine (M.O.) and Laboratory Medicine (A.M., P.S.), Bruneck Hospital, Bruneck, Italy.
-
- Georg Schett
- From the Department of Neurology (S.K., G.W., W.P., J.W.), Innsbruck University Clinic, Innsbruck, Austria; Division of Rheumatology (G.S., K.R., J.S.), Department of Internal Medicine III, University of Vienna, Vienna, Austria; and Departments of Internal Medicine (M.O.) and Laboratory Medicine (A.M., P.S.), Bruneck Hospital, Bruneck, Italy.
-
- Gregor Wenning
- From the Department of Neurology (S.K., G.W., W.P., J.W.), Innsbruck University Clinic, Innsbruck, Austria; Division of Rheumatology (G.S., K.R., J.S.), Department of Internal Medicine III, University of Vienna, Vienna, Austria; and Departments of Internal Medicine (M.O.) and Laboratory Medicine (A.M., P.S.), Bruneck Hospital, Bruneck, Italy.
-
- Kurt Redlich
- From the Department of Neurology (S.K., G.W., W.P., J.W.), Innsbruck University Clinic, Innsbruck, Austria; Division of Rheumatology (G.S., K.R., J.S.), Department of Internal Medicine III, University of Vienna, Vienna, Austria; and Departments of Internal Medicine (M.O.) and Laboratory Medicine (A.M., P.S.), Bruneck Hospital, Bruneck, Italy.
-
- Martin Oberhollenzer
- From the Department of Neurology (S.K., G.W., W.P., J.W.), Innsbruck University Clinic, Innsbruck, Austria; Division of Rheumatology (G.S., K.R., J.S.), Department of Internal Medicine III, University of Vienna, Vienna, Austria; and Departments of Internal Medicine (M.O.) and Laboratory Medicine (A.M., P.S.), Bruneck Hospital, Bruneck, Italy.
-
- Agnes Mayr
- From the Department of Neurology (S.K., G.W., W.P., J.W.), Innsbruck University Clinic, Innsbruck, Austria; Division of Rheumatology (G.S., K.R., J.S.), Department of Internal Medicine III, University of Vienna, Vienna, Austria; and Departments of Internal Medicine (M.O.) and Laboratory Medicine (A.M., P.S.), Bruneck Hospital, Bruneck, Italy.
-
- Peter Santer
- From the Department of Neurology (S.K., G.W., W.P., J.W.), Innsbruck University Clinic, Innsbruck, Austria; Division of Rheumatology (G.S., K.R., J.S.), Department of Internal Medicine III, University of Vienna, Vienna, Austria; and Departments of Internal Medicine (M.O.) and Laboratory Medicine (A.M., P.S.), Bruneck Hospital, Bruneck, Italy.
-
- Josef Smolen
- From the Department of Neurology (S.K., G.W., W.P., J.W.), Innsbruck University Clinic, Innsbruck, Austria; Division of Rheumatology (G.S., K.R., J.S.), Department of Internal Medicine III, University of Vienna, Vienna, Austria; and Departments of Internal Medicine (M.O.) and Laboratory Medicine (A.M., P.S.), Bruneck Hospital, Bruneck, Italy.
-
- Werner Poewe
- From the Department of Neurology (S.K., G.W., W.P., J.W.), Innsbruck University Clinic, Innsbruck, Austria; Division of Rheumatology (G.S., K.R., J.S.), Department of Internal Medicine III, University of Vienna, Vienna, Austria; and Departments of Internal Medicine (M.O.) and Laboratory Medicine (A.M., P.S.), Bruneck Hospital, Bruneck, Italy.
-
- Johann Willeit
- From the Department of Neurology (S.K., G.W., W.P., J.W.), Innsbruck University Clinic, Innsbruck, Austria; Division of Rheumatology (G.S., K.R., J.S.), Department of Internal Medicine III, University of Vienna, Vienna, Austria; and Departments of Internal Medicine (M.O.) and Laboratory Medicine (A.M., P.S.), Bruneck Hospital, Bruneck, Italy.
抄録
<jats:p> <jats:bold> <jats:italic>Background—</jats:italic> </jats:bold> Osteoprotegerin is a novel member of the tumor necrosis factor receptor superfamily and a soluble decoy receptor of the receptor activator of nuclear factor-κB ligand. Recent experimental research has implicated osteoprotegerin in atherogenesis, but epidemiological confirmation of this concept is sparse. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods and Results—</jats:italic> </jats:bold> As part of the prospective, population-based Bruneck Study, severity, initiation, and progression of atherosclerosis were assessed in carotid arteries. Cases of incident cardiovascular disease and vascular mortality were carefully recorded over a 10-year period (1990 to 2000). Osteoprotegerin levels were measured in samples obtained at baseline and during follow-up. Serum osteoprotegerin showed a strong association with numerous vascular risk factors, including age, diabetes, markers of systemic inflammation, chronic infection, and smoking. In multivariate analyses, osteoprotegerin was significantly related to severity and 10-year progression of carotid atherosclerosis. Furthermore, a high level of osteoprotegerin was an independent risk factor for incident cardiovascular disease (adjusted relative risk for the top versus bottom tertile group for osteoprotegerin 2.2 [1.3 to 3.8]; <jats:italic>P</jats:italic> =0.001) and vascular mortality (adjusted relative risk for the top versus bottom tertile group for osteoprotegerin 3.1 [1.2 to 8.2]; <jats:italic>P</jats:italic> =0.010) but not for mortality due to nonvascular causes. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> Osteoprotegerin is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. </jats:p>
収録刊行物
-
- Circulation
-
Circulation 109 (18), 2175-2180, 2004-05-11
Ovid Technologies (Wolters Kluwer Health)
- Tweet
詳細情報
-
- CRID
- 1360855569424649472
-
- NII論文ID
- 30022670261
-
- ISSN
- 15244539
- 00097322
-
- データソース種別
-
- Crossref
- CiNii Articles